Xeljanz ER (Tofacitinib ER)

Save over 84% with international version of Xeljanz ER from Pfizer and over 92% with generic Xeljanz ER.

Click here for information on Sun Pharma generics (Immediate availability)

For Brand Xeljanz ER - Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

Information about Xeljanz ER (Tofacitinib ER)

Xeljanz ER is a modified-release formulation of tofacitinib, which works by inhibiting Janus kinases (JAKs), enzymes that contribute to the inflammatory processes seen in autoimmune diseases. This extended-release version provides a once-daily dose, offering greater convenience compared to the immediate-release version. Xeljanz ER is primarily used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Product Highlights

• Xeljanz ER is indicated for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate or other DMARDs (disease-modifying antirheumatic drugs).
• It is also indicated for the treatment of active psoriatic arthritis, helping to manage symptoms such as joint pain and swelling.
• Xeljanz ER is used for the treatment of moderate to severe ulcerative colitis in adults, particularly those who have not responded to other treatments.
• Xeljanz ER may also be used for other autoimmune diseases as directed by a healthcare provider, depending on individual needs.

Key Ingredient

• Tofacitinib

Key Benefits

• Xeljanz ER effectively reduces inflammation, helping to alleviate symptoms such as joint pain, stiffness, and swelling in diseases like rheumatoid arthritis and psoriatic arthritis.
• By controlling inflammation, Xeljanz ER helps prevent further joint damage and improves overall function and mobility.
• The extended-release formulation allows for once-daily dosing, which can enhance patient adherence and simplify treatment plans.
• Xeljanz ER is useful for patients who have not responded well to conventional treatments like methotrexate or biologics.

Direction of Use

• The typical starting dose for Xeljanz ER is 11 mg once daily, though the exact dose may vary depending on the condition being treated. Your doctor will modify your dose based on your specific needs. 
• Xeljanz ER should be taken by mouth once a day, with or without food. Take the tablet whole; do not crush, split, or chew it. 
• If you forget a dose, take it as soon as you recall, unless it’s nearly time for your next dose. Avoid taking an additional dose to compensate for a missed one. 
• Try to take Xeljanz ER at the same time each day to help you remember and maintain a consistent level of the medication in your body.

Safety Concerns

• Xeljanz ER may increase the risk of serious infections, including tuberculosis and other opportunistic infections. Patients should be screened for infections before starting treatment and monitored during therapy.
• Xeljanz ER can affect liver function, so liver enzymes should be monitored regularly.
• There is an increased risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) in patients taking Xeljanz ER, especially at higher doses. Patients with a history of blood clots should use caution.
• Long-term use may increase the risk of certain cancers, including lymphoma and other malignancies.
• Xeljanz ER can increase cholesterol levels, so lipid monitoring is advised during treatment.
• It may increase the risk of bone fractures, particularly in patients with pre-existing bone conditions or those using higher doses.

Avoid Xeljanz ER (Tofacitinib ER) If

• Do not use Xeljanz ER if you have any active infections, as it may suppress your immune system and make infections harder to treat.
• If you have a history of deep vein thrombosis, pulmonary embolism, or other blood clotting disorders, avoid Xeljanz ER, as it can increase the risk of blood clots.
• Xeljanz ER should not be used in patients with severe liver impairment, as it may worsen liver function.
• Xeljanz ER is not recommended during pregnancy unless the potential benefits outweigh the risks. It is also contraindicated during breastfeeding due to potential risks to the infant.
• If you have had a severe allergic reaction to tofacitinib or any of its ingredients, do not use Xeljanz ER. 

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.